Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) Equity Average (2016 - 2026)

Cumberland Pharmaceuticals' Equity Average history spans 15 years, with the latest figure at $25.3 million for Q4 2025.

  • On a quarterly basis, Equity Average rose 7.06% to $25.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.3 million, a 7.06% increase, with the full-year FY2025 number at $23.7 million, down 9.05% from a year prior.
  • Equity Average hit $25.3 million in Q4 2025 for Cumberland Pharmaceuticals, down from $26.9 million in the prior quarter.
  • Over the last five years, Equity Average for CPIX hit a ceiling of $47.3 million in Q2 2021 and a floor of $23.7 million in Q4 2024.
  • Historically, Equity Average has averaged $34.7 million across 5 years, with a median of $36.1 million in 2023.
  • Biggest five-year swings in Equity Average: tumbled 30.34% in 2024 and later grew 7.06% in 2025.
  • Tracing CPIX's Equity Average over 5 years: stood at $44.6 million in 2021, then dropped by 16.12% to $37.4 million in 2022, then fell by 13.29% to $32.5 million in 2023, then dropped by 27.1% to $23.7 million in 2024, then grew by 7.06% to $25.3 million in 2025.
  • Business Quant data shows Equity Average for CPIX at $25.3 million in Q4 2025, $26.9 million in Q3 2025, and $28.0 million in Q2 2025.